Home  »  Business   »  Sorrento Therapeutics Inc. (NASDAQ:SRNE) Is Down -...

Sorrento Therapeutics Inc. (NASDAQ:SRNE) Is Down -13.21% Over The Past 30 Days: Is There Trouble Ahead?

In last trading session, Sorrento Therapeutics Inc. (NASDAQ:SRNE) saw 4.89 million shares changing hands with its beta currently measuring 2.19. Company’s recent per share price level of $1.38 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $651.21M. That closing price of SRNE’s stock is at a discount of -373.19% from its 52-week high price of $6.53 and is indicating a premium of 16.67% from its 52-week low price of $1.15. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.6 million shares which gives us an average trading volume of 7.50 million if we extend that period to 3-months.

For Sorrento Therapeutics Inc. (SRNE), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.25 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Sorrento Therapeutics Inc. (NASDAQ:SRNE) trade information

SRNE remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $1.38 price level, adding 9.21% to its value on the day. Sorrento Therapeutics Inc.’s shares saw a change of -70.32% in year-to-date performance and have moved -9.21% in past 5-day. Sorrento Therapeutics Inc. (NASDAQ:SRNE) showed a performance of -13.21% in past 30-days. Number of shares sold short was 60.67 million shares which calculate 8.98 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $5.00 to the stock, which implies a rise of 72.4% to its current value. Analysts have been projecting $5.00 as a low price target for the stock while placing it at a high target of $5.00. It follows that stock’s current price would drop -262.32% in reaching the projected high whereas dropping to the targeted low would mean a loss of -262.32% for stock’s current value.

Sorrento Therapeutics Inc. (SRNE) estimates and forecasts

The company is estimating its revenue growth to increase by 56.10% in the current quarter and calculating 35.00% increase in the next quarter. This year revenue growth is estimated to rise 1.10% from the last financial year’s standing.

1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $11.69 million for the same. And 1 analysts are in estimates of company making revenue of $11.92 million in the next quarter that will end on Dec 2022. Company posted $12.06 million and $13.08 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -3.10% while estimating it to be -8.80% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -3.70% during past 5 years. In 2022, company’s earnings growth rate is likely to be around -11.90% while estimates for its earnings growth in next 5 years are of 37.00%.

SRNE Dividends

Sorrento Therapeutics Inc. is more likely to be releasing its next quarterly report on May 11 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Sorrento Therapeutics Inc. (NASDAQ:SRNE)’s Major holders

Insiders are in possession of 1.61% of company’s total shares while institution are holding 34.51 percent of that, with stock having share float percentage of 35.08%. Investors also watch the number of corporate investors in a company very closely, which is 34.51% institutions for Sorrento Therapeutics Inc. that are currently holding shares of the company. State Street Corporation is the top institutional holder at SRNE for having 39.66 million shares of worth $79.72 million. And as of Jun 29, 2022, it was holding 8.81% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 33.95 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 7.55% of outstanding shares, having a total worth of $68.24 million.

On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2022, the former fund manager was holding 31.83 million shares of worth $49.97 million or 7.07% of the total outstanding shares. The later fund manager was in possession of 10.9 million shares on Jun 29, 2022, making its stake of worth around $21.9 million in the company or a holder of 2.42% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]